Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
Author of the short article: https://secure.gravatar.com/avatar/dacbb4d6d68d06d07a0d4253aaa78393?s=70&d=mp” alt=”GlobeNewswire” aria-labelledby=”wire-company-name” height=”70″ width=”70″> Released Mar 04, 2024 – 5 minute checked out MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®**(ranibizumab injection)for….